SUBJECT TO COMPLETION, DATED DECEMBER 22, 2023MARCH 8, 2024
PRELIMINARY PROSPECTUS
UP TO 1,152,073 SHARES OF COMMON STOCK
1,152,073 PRE-FUNDED WARRANTS TO PURCHASE UP TO 1,152,073 SHARES OF COMMON STOCK
1,152,073 SHARES OF COMMON STOCK UNDERLYING THE PRE-FUNDED WARRANTS
1,152,073 COMMON WARRANTS TO PURCHASE UP TO 2,304,146 SHARES OF COMMON STOCK
2,304,146 SHARES OF COMMON STOCK UNDERLYING THE COMMON WARRANTS
This is a best efforts public offering of up to 1,152,073 shares of our common stock, par value $0.001 per share, together with warrants to purchase an aggregate of 2,304,146 shares of our common stock (the “Common Warrants”) at an assumed combined public offering price of $$6.51 per share and one Common Warrant to purchase two shares of our common stock (the last reported sale price per share of our common stock on the Nasdaq Capital Market on , 2023)March 6, 2024). We are also offering pre-funded warrants to purchase up to 1,152,073 shares of our common stock (the “Pre-Funded Warrants”) and the shares of common stock issuable upon exercise of the Pre-Funded Warrants, in lieu of shares of common stock, to those investors whose purchase of shares of our common stock in this offering would result in the investor, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the investor, 9.99%) of our outstanding common stock immediately following the consummation of this offering. Each Pre-Funded Warrant will be exercisable for one share of our common stock. Each Pre-Funded Warrant is being sold together with aone Common Warrant to purchase sharetwo shares of our common stock. Each Pre-Funded Warrant and the accompanying Common Warrant will be offered at an offering price equal to the public offering price at which a share of common stock and accompanying Common Warrant is being offered, minus $0.001. The exercise price of the Pre-Funded Warrants will be $0.001 per share, and the Pre-Funded Warrants will be immediately exercisable and may be exercised at any time until exercised in full. For each Pre-Funded Warrant we sell, the number of shares of common stock we are offering will be decreased on a one-for-one basis. The number of Common Warrants sold in this offering will not change as a result of a change in the mix of the shares of our common stock and Pre-Funded Warrants sold. The exercise price of the Common Warrants will be $ per share ( % of the combined public offering price per share and accompanying Common Warrant), and the Common Warrants will be exercisable immediately upon issuance and will expire five years from the date of issuance. This offering also relates to the shares of common stock issuable upon exercise of any Pre-Funded Warrants and any Common Warrants. The shares of common stock and Pre-Funded Warrants, and the accompanying Common Warrants, can only be purchased together in this offering but will be issued separately and will be immediately separable upon issuance.
Our common stock is currently listed on the Nasdaq Capital Market under the symbol “BPTH.” On , 2023,March 6, 2024, the last reported sales price per share of our common stock on the Nasdaq Capital Market was $ .$6.51. All share, Pre-Funded Warrant and Common Warrant numbers are based on an assumed combined public offering price of $$6.51 per share or Pre-Funded Warrant and accompanying Common Warrant. The actual public offering price per share of common stock and accompanying Common Warrant and any Pre-Funded Warrant and accompanying Common Warrant, as the case may be, will be determined between us, the Placement Agent (as defined below) and the investors at the time of pricing, and may be at a discount to the current market price. Therefore, the assumed public offering price used throughout this prospectus may not be indicative of the final offering price. There is no established public trading market for the Pre-Funded Warrants or the Common Warrants, and we do not expect a market to develop. In addition, we do not intend to list the Pre-Funded Warrants or the Common Warrants on the Nasdaq Capital Market, any other national securities exchange or any other nationally recognized trading system.
Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described in the section titled “Risk Factors” on page 7 of this prospectus and under similar headings in the other documents that are incorporated by reference into this prospectus. | | | Per Share and Accompanying Common Warrant | | | Per Pre- Funded Warrant and Accompanying Common Warrant | | | Total | |
Offering price | | | | $ | | | | | | $ | | | | | | $ | | | |
Placement agent fees(1) | | | | $ | | | | | | $ | | | | | | $ | | | |
Proceeds, before expenses, to us(2) | | | | $ | | | | | | $ | | | | | | $ | | | |
(1)
Represents a cash fee equal to % of the aggregate purchase price paid by investors in this offering. In addition, we have agreed to reimburse the Placement Agent for certain expenses. See “Plan of Distribution” on page 21 of this prospectus for more information.
(2)
The amount of the offering proceeds to us presented in this table does not give effect to the exercise, if any, of the Pre-Funded Warrants or the Common Warrants.
We have engaged Roth Capital Partners, LLC as our exclusive placement agent (“Roth” or the “Placement Agent”) to use its reasonable best efforts to solicit offers to purchase our securities in this offering. The Placement Agent has no obligation to purchase any of the securities from us or to arrange for the purchase or sale of any specific number or dollar amount of the securities. Because there is no minimum offering amount required as a condition to closing in this offering the actual public offering amount, Placement Agent’s fee, and proceeds to us, if any, are not presently determinable and may be substantially less than the total maximum offering amounts set forth above and throughout this prospectus. We have agreed to pay the Placement Agent the Placement Agent fees set forth in the table above. See “Plan of Distribution” in this prospectus for more information. There is no arrangement for funds to be received in escrow, trust or similar arrangement. Because there is no escrow account and no minimum number of securities or amount of proceeds, investors could be in a position where they have invested in us, but we have not raised sufficient proceeds in this offering to adequately fund the intended uses of the proceeds as described in this prospectus. We will bear all costs associated with the offering. This offering will end within three trading days from the date of this prospectus, but no later than .April 15, 2024
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed on the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.
Delivery of the shares of common stock, Pre-Funded Warrants and Common Warrants offered hereby is expected to take place on , 2023,2024, subject to satisfaction of certain conditions.
Roth Capital Partners
Prospectus dated , 20232024